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 2 
Abstract 36 
Aims An excessive production of aldosterone influences outcome in patients with heart 37 
failure (HF) and in obese patients. Findings from laboratory studies suggest that chronic 38 
aldosterone blockade maybe more beneficial in abdominally obese HF prone rats. In the 39 
current study, we investigated if the clinical response to a mineralocorticoid receptor 40 
antagonist in mildly symptomatic HF patients varied by abdominal obesity.  41 
Methods and Results 2587 NYHA class II, low ejection fraction HF patients enrolled in the 42 
EMPHASIS-HF trial were randomly assigned to eplerenone and placebo. In this post-hoc 43 
analysis, patients were categorized according to waist circumference (normal if WC < 102 cm 44 
in men and < 88 cm women; abdominal obesity if NWC≥ 102cm in men and ≥88cm women). 45 
The potential statistical interaction between the treatment and WC was assessed on the 46 
primary endpoint of death from cardiovascular causes or hospitalization for HF and other 47 
secondary endpoints. Over a median follow-up of 21 months, a significant benefit of 48 
eplerenone for the primary outcome was noted in both normal (HR 0.77, CI95% 0.61-0.98, 49 
p=0.03) and increased (HR 0.48, CI95% 0.37-0.63, p<0.0001) WC subgroups but the latter 50 
patients appeared to receive greater benefit than patients with normal WC (p for interaction 51 
0.01). This suggests a significant quantitative (treatment effect varies in magnitude by 52 
subgroup, but is always in same direction) rather than a qualitative interaction (direction of 53 
the treatment effect varies by subgroup) between eplerenone and WC in the adjusted analysis. 54 
Mean doses of eplerenone, blood pressure and serum potassium changes and adverse events 55 
were similar between WC subgroups.  56 
Conclusion In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and 57 
without abdominal obesity, although the benefit appeared to be more pronounced among 58 
those with abdominal obesity. The findings are potentially hypothesis generating and needs to 59 
be replicated in other HFrEF populations.  60 
 61 
Keywords Abdominal obesity; Heart failure with reduced ejection fraction; Eplerenone 62 
63 
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Introduction 64 
 65 
Obesity is recognized as a cardiovascular risk factor and the worldwide epidemics of obesity 66 
parallels the one observed for HF.1-3 It is associated with increased risk of cardio renal disease, 67 
including hypertension, coronary artery disease and adverse cardiac remodelling (left 68 
ventricular hypertrophy and dilation), and progression towards HF.4 On another hand obese 69 
subjects have higher aldosterone levels, which may result in mineralocorticoid receptor (MR) 70 
over activation. Reciprocally, higher aldosterone levels have been implicated in the 71 
development and maintenance of obesity.5-7 72 
Mineralocorticoid receptor antagonist (MRA) therapy improves outcomes in patients with 73 
chronic systolic HF with mild symptoms (EMPHASIS-HF trial), acute symptomatic systolic 74 
HF in post myocardial infarction (EPHESUS trial) and in severe NYHA stage III-IV systolic 75 
HF (RALES trial).8-10 However, to the best of our knowledge the influence of established 76 
overweight or obesity on the response to MRAs is unknown. Studies in obese non-HF patients 77 
with or without associated metabolic disorder11 suggested that MRA therapy improved left 78 
ventricular function and myocardial abnormalities with concurrent decreases of circulating 79 
fibrotic markers. Knowing that visceral fat is a source of serum aldosterone and that several 80 
experimental studies7, 12-14 have implicated aldosterone as an important mediator of obesity-81 
related cardiovascular risk, we have recently published the first experimental data suggesting 82 
that as compared to leaner counterparts, viscerally-obese heart failure prone rats may further 83 
benefit from chronic MRA treatment 15. Yet no study has specifically evaluated whether 84 
clinical response to a MRA over a long follow-up period might be better in HF patients with 85 
vs. without abdominal obesity. 86 
In this context, we sought for the first time to evaluate the interaction between increased 87 
adiposity estimated by the waist circumference (WC) and body mass index (BMI, as reference 88 
obesity measurement parameter) and the clinical benefit from the MR antagonist eplerenone 89 
in patients with congestive HF receiving recommended therapy for systolic HF (ejection 90 
fraction below 35%) and enrolled in the EMPHASIS-HF trial.10 91 
 92 
 93 
Methods 94 
The design, patient eligibility criteria, study procedure and main results of the EMPHASIS-95 
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HF study have been previously reported.10 In brief, in this randomized double-blind trial, 96 
patients with New York Heart Association class II heart failure and an ejection fraction of no 97 
more than 35% (HFrEF) were randomly assigned to receive eplerenone (up to 50 mg daily) or 98 
placebo, in addition to recommended therapy.  99 
Study outcomes 100 
The same primary and secondary outcomes were used in the current analysis as in the main 101 
study.10 Briefly, the primary outcome was the composite of death from cardiovascular causes 102 
or first hospitalization for HF. The pre-specified adjudicated secondary outcomes were 103 
respectively all cause death, cardiovascular death and hospitalization for HF. For continuous 104 
variables, the baseline value was defined according to the EMPHASIS-HF statistical analysis 105 
plan as the measurement that was made on the closest date prior to the study medication 106 
starting date. If there were more than one measurement made on the same date, the average 107 
value of these data was calculated and used as the baseline measurement.  108 
Because the following variables did not fulfil the assumption of log-linearity, WC and BMI 109 
were not analysed as continuous variables but as categorical variables. 110 
Waist circumference 111 
Baseline measurement of WC was performed by a tape measure placed around subject’s bare 112 
abdomen just above subject’s hipbone, at the level of the subject’s navel, when the relaxed 113 
subject exhaled. The tape measure was positioned parallel to the floor without compressing 114 
the subject’s skin. Values were considered aberrant and were excluded from the data analysis 115 
when WC < 60 cm.  116 
Subjects were divided into two WC groups according to the American Heart Association 117 
(AHA) defined cutoffs.16 Men and women with WC values <102 and <88 cm, respectively, 118 
were considered to have a normal WC (NWC group), whereas those with WC values ≥102 119 
and ≥88 cm respectively were considered to have high WC (HWC group) and harbour an 120 
abdominal obesity. Subjects were further categorized according to WC quintiles taking into 121 
account sex differences. 122 
 123 
Body mass index 124 
Body mass index is defined as the weight in kilograms divided by the square of the height in 125 
meters (kg/m2). BMI values were considered missing when height or weight measures were 126 
not reported. Obesity was defined according to the WHO BMI classification 127 
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(http://apps.who.int/bmi/index.jsp?introPage=intro_3.html): BMI≥30 kg/m2 were classified was obese 128 
patients while BMI values <30 kg/m2 characterized normal weighted and overweight patients.  129 
Statistical analysis 130 
Waist circumference and BMI were the key explanatory variables. Continuous variables are 131 
expressed as mean ± standard deviation (m±SD), categorical variables as frequencies 132 
(percentage). Comparisons of baseline characteristics between WC or BMI groups were 133 
performed using Student t-test or Mann-Whitney or chi-Square test as required. Risk 134 
probabilities were calculated using the Kaplan-Meier method and plotted as survival curves.  135 
Hazard ratios and respective 95% confidence intervals were estimated using univariable and 136 
multivariable Cox proportional hazard regression models. Assumptions of log-linearity, 137 
absence of multi-colinearity and hazards proportionality were thoroughly verified.  138 
Interactions between BMI or WC and eplerenone effect on outcomes were assessed by 139 
introducing an interaction term (BMI or WC variable*eplerenone) in crude (i.e. BMI or WC, 140 
eplerenone, BMI or WC*eplerenone) and adjusted models. The following candidate 141 
covariates were considered for adjustment: age, gender, heart rate, systolic blood pressure, left 142 
ventricular ejection fraction, QRS duration, medical history (hospitalization for HF, 143 
hypertension, angina pectoris, myocardial infarction, coronary artery angioplasty, coronary 144 
artery bypass surgery, atrial fibrillation or flutter, diabetes mellitus, stroke), device therapy 145 
(implantable cardioverter-defibrillator, cardiac-resynchronization therapy, implantable 146 
cardioverter-defibrillator with cardiac resynchronization), blood sodium, blood potassium, 147 
estimated glomerular filtration rate and use of diuretics, angiotensin converting enzyme 148 
(ACE) inhibitors or angiotensin receptor blockers (ARB), beta-blockers, and lipid-lowering 149 
agents. Among these candidate covariates, variables significantly associated with the outcome 150 
of interest with a p-value < 0.15 on univariable cox regression 17  were further selected using 151 
an interactive backward selection process. Only the covariates associated with the outcome of 152 
interest with a p-value < 0.05 were retained in multivariable models.  153 
In addition, we evaluated the functional form of the interaction between treatment and 154 
WC/BMI with regards to the risk of outcomes using WC/BMI as a non-linear continuous 155 
variable. To do so, we used restricted cubic splines and plotted the hazard ratios of treatment 156 
effect according to WC/BMI calculated from the Cox model. 157 
Adverse events and those leading to permanent study drug withdrawal were presented 158 
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according to WC or BMI category groups.  159 
Statistical interaction has come into increasing use in trial analysis. Given the low power of 160 
interaction tests, selected a priori a 0.10 cut-off threshold for the interaction p value has been 161 
used. As a consequence, a p-value of <0.05 was considered statistically significant for the 162 
main effects and <0.10 for the interaction terms.  163 
 164 
All analyses were performed using software SAS version 9.4 (SAS Institute Inc., Cary, N.C., 165 
USA). 166 
 167 
Results 168 
Clinical characteristics  169 
Of the 2737 patients randomized in EMPHASIS-HF, 2579 were included in the WC analysis 170 
(158 patients had a missing or implausible WC value). Median WCs were 100 cm (IQR92-171 
108) and 94 cm (IQR85-104) in men and women respectively and 1295 patients (50.2%) had 172 
a HWC (abdominal obesity if WC ≥102 cm for men and ≥88 cm for women). The remaining 173 
1284 individuals had a NWC (if WC <102 cm for men and <88 cm for women) (Table1, 174 
TableS1). Patients with a HWC had more obesity-related disorders such as hypertension, 175 
atrial fibrillation and diabetes mellitus, as compared to patients with a NWC (Table1). 176 
However, there were no clinically significant differences between patients allocated to 177 
eplerenone or placebo within the two WC subgroups (Table S1).  178 
 Of the 2737 patients randomized in EMPHASIS-HF, 2722 were included in the BMI analysis 179 
(15 patients had a missing or implausible BMI value). The median BMI was 27 kg/m2 180 
(IQR24-30) and 739 patients (27.1%) had a global obesity with BMI≥30 kg/m2 and 1983 181 
(72.9%) a BMI<30 kg/m2. Like patients with a HWC, those with a high BMI had more 182 
obesity-related disorders, as compared to patients with a BMI<30 kg/m2 (Table1).  183 
The median follow-up duration among all patients was 21 months (IQR: 10 to 33 months). 184 
 185 
Eplerenone safety profile across subgroups 186 
Adverse events leading to eplerenone withdrawal occurred in 101(15.7%) NWC patients as 187 
compared to 74 (11.5%) HWC patients (p=0.034) leading to a p of interaction value of 0.01 188 
(TableS2). Hyperkalaemia adverse events and hyperkalaemia leading to study drug 189 
discontinuation occurred equally in WC and BMI eplerenone subgroups respectively 190 
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(TableS2). 191 
Mean doses achieved across subgroups 192 
The mean dose of eplerenone did not different between WC subgroups (p=0.67). Among 193 
patients assigned to eplerenone, 61.4 % and 62.3% of the HWC and NWC groups, 194 
respectively, received the highest daily dose (50 mg daily, p=0.81). Likewise, the mean dose 195 
of eplerenone did not differ between BMI subgroups (p=0.79) and 60.8% of the 196 
BMI≥30kg/m2 patients against 61.6% of the BMI<30kg/m2 groups received the highest daily 197 
dose eplerenone (50 mg daily, p=0.96).  198 
Effect of eplerenone on clinical outcomes 199 
Overall, there were fewer primary endpoints in the eplerenone group in EMPHASIS-HF (HR 200 
0.63, 95% CI 0.52-0.75). This was also the case for other outcomes, including all-cause 201 
mortality (HR 0.76, 95% CI 0.61-0.94) cardiovascular mortality (HR 0.73, 95% CI 0.58-0.93) 202 
and hospitalization for heart failure (HR 0.59, 95% CI 0.48-0.73) (Figures 1 and 2).  203 
When analysing according to WC and BMI anthropomorphic subgroups, no differential effect 204 
of the treatment was observed on blood pressure, heart rate, body weight and serum potassium 205 
levels, expressed as changes from baseline to month 1 and month 5-post randomisation (data 206 
not shown).  207 
Interaction between abdominal obesity and the effects of eplerenone  208 
The modifying effect of abdominal obesity on the impact of eplerenone for each outcome is 209 
shown in figures 1 and 2. The effect of eplerenone on the primary outcome was significant in 210 
both patients with HWC (multivariable HR 0.48, 95% CI 0.37-0.63) and in patients with a 211 
NWC (multivariable HR 0.77, 95% CI 0.61-0.98), but significantly stronger in the HWC 212 
group as demonstrated by a p value for the interaction of 0.01 (Figure 1A, Figure 2A). 213 
Importantly, abdominal obesity i.e. HWC was not associated with the primary outcome in the 214 
placebo group (multivariable HR 0.96, 95% CI 0.76-1.20) whereas it was associated with 215 
lower rates for the primary events in the eplerenone group (multivariable HR 0.60, 95% CI 216 
0.45-0.80), resulting in a significant interaction between eplerenone and HWC in the adjusted 217 
analysis (p=0.01).  218 
Overall, similar patterns were observed for the secondary outcomes but the interaction 219 
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between eplerenone and HWC reached statistical significance only for “Death from 220 
cardiovascular causes” and “Hospitalization for HF” secondary outcomes (p for interaction 221 
0.09 and 0.07 respectively) (Figure2). In addition, we identified a significant interaction in 222 
men between treatment and WC within the model using restricted cubic splines (Figure3) (p 223 
value for the interaction p=0.025 in the adjusted model, Figure3A). The shape of the 224 
association is difficult to assess in women given the wide confidence intervals resulting from 225 
the small number of patients within the subset of female patients. In this subset, the 226 
interaction did not reach statistical significance (p=0.30 in the adjusted model, Figure3B). 227 
Likewise the interaction between treatment and BMI for both genders using restricted cubic 228 
splines did not reached significance (p=0.15 in the adjusted model, Figure3C). 229 
Overall both WC groups derived significant benefit from eplerenone for the primary outcome 230 
and hospitalization for heart failure with quantitatively greater benefits derived from the 231 
treatment in patients with abdominal obesity from the HWC subgroup. A lower dropout rate 232 
was observed in patients randomized to eplerenone when they had HWC, which could 233 
contribute to the higher treatment effect observed in this subgroup and further suggests a net 234 
higher benefit to risk ratio in the HWC group. A sensitivity analysis censoring the follow-up 235 
up to the time of permanent drug discontinuation yielded interaction still suggesting a higher 236 
benefit to risk ratio in the HWC group. 237 
While analysing the EMPHASIS-HF population using WC quintiles, we observed lower HR 238 
for the primary outcome in patients within the 3rd to 5th quintile (i.e. ≥97cm in men and 239 
≥90cm in women) than in patients within the first two quintiles (TableS3) with a significant p 240 
value for interaction between eplerenone and WC of p=0.09. Interestingly, multivariable HR 241 
in the 3rd to 5th quintile ranged from 0.47 (95% CI 0.32-0.71) to 0.53 (95% CI 0.34-0.82) 242 
whereas the HRs of the first two quintiles were 0.70 (95% CI 0.49-1.00) and 0.94 (95% CI 243 
0.64-1.37). Of note, these cut-offs (i.e. ≥97 cm in men and ≥90 cm in women) within the 244 
EMPHASIS-HF population were below and above the cut-offs defining abdominal obesity in 245 
men and women respectively.  246 
 247 
Interaction between of BMI and the effects of eplerenone 248 
The benefit of eplerenone on the rate of the primary outcome seemed to be greater in obese 249 
(BMI≥30kg/m2) patients (multivariable HR 0.49, 95% CI 0.35-0.71) than in patients with a 250 
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BMI<30kg/m2 (multivariable HR 0.69, 95% CI 0.57-0.83) but the difference is not as marked 251 
as for WC and the p-value of interaction between BMI and eplerenone was greater than 0.10 252 
(p=0.11, Figure 2, Table2). Similar observations were done for secondary outcomes, with no 253 
significant interaction in the adjusted analyses between BMI and the effect of eplerenone 254 
(Table2). When analysed according to the median BMI value of 27kg/m2, the benefit of 255 
eplerenone on the rate of the primary outcome was greater in patients with BMI≥27kg/m2 256 
(multivariable HR 0.50, 95% CI 0.38-0.65) than in patients with BMI<27kg/m2 (multivariable 257 
HR 0.76, 95% CI 0.61-0.94; p for interaction P=0.018) (Table S4). These results of BMI 258 
analyses with a cut-off defined at 27 kg/m² and 30 kg/m² (Tables S4 and 2 respectively) are 259 
confirmed by the shape of the association in adjusted model between Eplerenone and the 260 
primary outcome according to the value of BMI when used as continuous variable (Figure 261 
3C). Risk of CVD or HHF is higher for values around 25 kg/m², while it decreases until a 262 
value of 30 kg/m², and then remains steady (Figure 3C). Likewise, the benefit of eplerenone 263 
on the rates of hospitalization for HF was greater in patients with a BMI≥27kg/m2 264 
(multivariable HR 0.44, 95% CI 0.33-0.62) than in patients with a BMI<27kg/m2 265 
(multivariable HR 0.68, 95% CI 0.52-0.88; p for interaction =0.051) (Table S4).  266 
 267 
Discussion  268 
The main finding of our post hoc analysis of the EMPHASIS-HF data suggest that patients 269 
with HF and reduced ejection fraction and mild symptoms who have abdominal obesity, 270 
derive greater benefit from eplerenone than those who are not obese or overweight. All 271 
HFrEF patients derived benefits from eplerenone in the EMPHASIS-HF trial, but the greater 272 
benefits afforded by eplerenone in HWC patients substantiated by the significant interaction 273 
between WC and eplerenone for three out of the four studied outcomes. This characterized for 274 
the first time a quantitative rather than a qualitative interaction between adiposity and the 275 
response to MRA therapy. Importantly, this greater benefit occurred with the use of similar 276 
doses of eplerenone and overall the benefit/risk ratio was more favourable since the rate of 277 
adverse events was not different among WC subgroups. Altogether this post hoc analysis of 278 
EMPHASIS-HF suggests that abdominal obesity estimated by waist circumference 279 
measurement could be a simple and straightforward classifier identifying a subset of patients 280 
with HF and reduced ejection fraction that might derive greater benefit from MRA therapy. 281 
Despite the known adverse impact of obesity on most of the HF risk factors, our results 282 
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suggest that a better prognosis of patients with abdominal obesity i.e. obesity paradox. Thus 283 
our results suggest for the first time that part of the known obesity paradox observed in HF 284 
trial might be explained by the greater benefits derived by obese patients from their HF MRA 285 
treatment.  286 
 287 
The deleterious impact of excessive aldosterone/MR activation in the heart has been 288 
extensively documented this past decade. Both cortisol and aldosterone adversely affect the 289 
cardiovascular events via the activation of the mineralocorticoid receptors in the heart, blood 290 
vessels, kidney and other sites.18 Notably, high levels of aldosterone promote the development 291 
of interstitial cardiac fibrosis, promote platelet aggregation and contribute to endothelial 292 
dysfunction in part by reducing nitric-oxide bioavailability and favour hypertension, chronic 293 
kidney disease as well as concentric left ventricular hypertrophy in the general community.19 294 
Furthermore MR activation in macrophages has been demonstrated to promote coronary and 295 
systemic inflammation particularly in the initial response to reperfusion injury after ischemic 296 
injury. 20, 21 Collectively those studies have justified the targeting of MR as new approach for 297 
the treatment of heart failure patients. 8, 10, 22 The mechanism of action of MRAs in HF is 298 
multiple including anti-inflammatory, anti-fibrotic and anti-remodelling properties and 299 
decrease in sympathetic drive and improves heart-rate variability. 23,24, 25 It could be in part 300 
attributed to the increased MR activation and more pronounced production of its ligands in 301 
the failing human heart. 4, 26, 27  302 
 303 
Experimental and clinical studies suggest that MR over activation in hyperphagic conditions 28 304 
and high fat diet induced obesity may precipitate cardiac remodelling and HF development. 13, 305 
29, 30 In fact, all components of the renin-angiotensin aldosterone system are expressed in 306 
adipose tissue and their gene expression has been found increased in adipose tissues of both 307 
obese animal models and obese humans. 7, 31, 32 The increments in body weight and overall 308 
obesity are known to result from chronic positive energy balance, a condition which is known 309 
to increase the MR expression and further favour the development of adipose tissue 310 
inflammation and fibrosis. 29 We recently demonstrated that chronic eplerenone treatment 311 
delayed the cardiac remodelling and HF onset in both lean and obese spontaneously 312 
hypertensive heart failure rats but that obese rats presenting a higher aldosterone level further 313 
benefited from MRA treatment through improvement of their obesity, dyslipidaemia and 314 
myocardial fibrosis. 15 Further experimental studies have demonstrated that the benefits of MR 315 
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blockade included reduced obesity-related cardiac fibrosis, coronary micro vascular disorders, 316 
and cardiac oxidative stress and systemic inflammation. 13, 30 Small exploratory clinical studies 317 
further suggested beneficial effects of spironolactone on left ventricular dysfunction in obese 318 
individuals without other comorbidities and in patients with metabolic syndrome, support our 319 
observation of a more pronounced clinical benefit of MRA therapy in overweight to obese 320 
individuals. 11, 23 It also suggests that overweight to obese HF patients may derive great benefit 321 
from MRA at least in part because of their high inflammatory and fibrotic clinical status. 33-35 322 
 323 
This is of strong interest when considering that in the USA approximately ½ to 2/3 of the HF 324 
patients are overweight or obese.36 Interestingly aldosterone was proposed to promote 325 
adipogenesis by inducing peroxisome proliferator activated receptor  expression, while 326 
increased adiposity is known to have adverse effects on LV structure and function, and other 327 
risk factors of HF including hypertension and coronary artery diseases.13, 37 Thus, although 328 
speculative in clinic but based on strong experimental evidence, one tentative explanation of 329 
the better response to eplerenone of HF patients with abdominal obesity might be that these 330 
patients have higher aldosterone levels associated with hyper-secretion of trophic factors from 331 
the visceral adipose tissue.5, 38 The observed better discriminative power of the WC parameters 332 
in defining the best responder group of HFrEF to eplerenone as compared to BMI, might be 333 
explained in part by the fact that the RAAS has been described to have variable activity 334 
depending on the adipose tissue location. A high RAAS activity has been reported in 335 
abdominal adipocytes, which are more closely associated with the aldosterone biosynthesis 336 
and where angiotensinogen and angiotensin II receptor gene expression levels are high. A 337 
lower RAAS activity was reported in gluteofemoral adipose tissue, which may explain why 338 
the fat from this latter location is less metabolically active.39 339 
Adipose tissue is considered as an endocrine organ influencing the maintenance of the body 340 
metabolic and inflammatory homeostasis especially when located in close vicinity with the 341 
heart, kidney, liver and the skeletal muscle. The development of visceral fat tissue results in 342 
crucial endocrine interactions with those vital organs that may lead to their structural and 343 
functional alterations.40,41  344 
While largely used to classify obesity, a clear limitation of BMI is that it is unable to 345 
distinguish between increased body fat content and increased lean body mass (breakdown of 346 
body composition) and cannot indicate where the adiposity preferentially develops as it is 347 
accountable for the characterization of a global obesity. Our results highlight the different 348 
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relevance of those two anthropometric parameters, and confirm that BMI and WC are not 349 
characterizing the same type of adiposity. Altogether a total of 668 EMPHASIS patients were 350 
“misclassified” when using BMI: 626 of them were non-obese (BMI<30kg/m2) but harboured 351 
an abdominal obesity (HWC) and 42 of them were classified obese (BMI≥30kg/m2) but had 352 
NWC. Those patients are the one discriminating the results between BMI and WC parameters 353 
and leading to the statistically significant results for the interaction in WC but not in BMI 354 
subgroups. All types of adipose fat depot are not alike and can differ by their location 355 
(gynoid, android, visceral, subcutaneous, overall) and degrees (from overweight up to morbid 356 
obesity). Numerous imaging tools, such as dual-energy X-ray absorptiometry, bioelectrical 357 
impedance analysis and magnetic resonance imaging and anthropometric measure like BMI 358 
and WC can discriminately evaluate them. Whether imaging data would better define the fat 359 
deposition thus better refine the subsequent risk is beyond the scope of our study, but WC is 360 
such an easy cost-less biomarker to access that its use in general clinic should be warranted. 361 
Moreover weight variation in HF patients is very much dependant on fluid retention, and the 362 
resulting congestion may mostly impact BMI and in a lesser extend WC. This suggests that 363 
the latter parameter might be more reliable in the context of HF. Our results suggest for the 364 
first time that the specific location of the excess of adiposity represents an important matter 365 
when treating HF patients. 366 
 367 
While still requiring replication, the differential findings reported for WC and BMI with 368 
regards to the patient response to eplerenone, is consistent with the large body of literature 369 
suggesting that depending on their location, adipose tissue deposits present distinct metabolic 370 
and inflammatory properties. While both subcutaneous and visceral adipose tissues are 371 
considered as endocrine organs, visceral adipose tissue has especially been shown to secrete 372 
adipocytokines and other vasoactive substances including aldosterone 24, 25 and has been 373 
associated with higher mortality than overall obesity defined by BMI. 42, 43 The increase in 374 
either or both types of fat deposit (subcutaneous and visceral) participates in the development 375 
of an abdominal obesity, which is readily and easily measurable with WC.  376 
 377 
Interestingly, our data show no differential effect of the treatment on blood pressure, 378 
heart rate, body weight and serum potassium levels, according to WC anthropomorphic 379 
subgroups, an hyperkalaemia adverse events including those leading to study drug 380 
discontinuation occurred equally in WC eplerenone subgroups. In addition, hypotension, 381 
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adverse events leading to eplerenone withdrawal occurred significantly less frequently in 382 
patients with increased abdominal adiposity. Taken together, our results suggest that the 383 
benefit/risk ratio of eplerenone therapy is higher in patients with abdominal obesity. 384 
Even though not verify here (the absence of available bio samples precluded us to reconcile 385 
the levels of MR ligands and the degree of abdominal adiposity in the EMPHASIS-HF 386 
patients), in clinic plasma aldosterone concentration correlated with increased adiposity 387 
measured by BMI and is associated with the development of metabolic syndrome with 388 
increased WC in the Framingham population and in African-American population. 26,27 It was 389 
thus expected that EMPHASIS obese patients presented worse clinical characteristics as 390 
compared to their lean counterparts. While overweight and obesity are demonstrated 391 
pejoratively impacting the risk of cardiovascular diseases in the general population, a reduced 392 
mortality in HF population with higher BMI values has been demonstrated and referred as 393 
obesity paradox. 44, 45 Clark et al demonstrated such paradox in advanced HF cohort (LVEF 394 
<25%) and increased WC was mostly associated with improved outcomes in advanced HF. 36, 395 
42 396 
Although our results suggest an improved response to MRA treatment of EMPHASIS HF 397 
patients as one out of many other possible contributors to the obesity paradox. Indeed, such 398 
paradox, also described in other pathophysiologic conditions, varies according to i) the 399 
aetiology of the wide range of clinical phenotypes observed in different HF cohorts restricting 400 
the protective effect of obesity to patients with non ischemic HF; ii) the patient gender; iii) the 401 
patient age; iv) the LVEF; v) the cumulative exposure to excess adiposity and resulting 402 
metabolic reserve; vi) the presence of diabetes. 35,37, 45-49 403 
One could extrapolate that what is called the HF obesity paradox 37, 42, 44, 46-48 described in 404 
other HF trials might also be a consequence of HF therapy being more effective in obese 405 
patients. This is at least suggested by the results of our study where abdominally obese 406 
patients are better responders to mineralocorticoid receptor antagonism then leaner 407 
participants. Interestingly, this potential better response to RAAS inhibitors based therapy is 408 
also suggested in the placebo group where more than 90% of the enrolled patients are already 409 
treated with ACE inhibitor or ARB and where those with increased adiposity did not 410 
demonstrated significant association with worsen outcomes. In other reports mentioning this 411 
HF obesity paradox phenomenon the association of BMI with outcomes was studied while 412 
adjusting for the background medical therapy, but the interaction of BMI with therapy are yet 413 
to be reported. Thus in-depth evaluation of the proposed paradoxical effect of obesity in HF 414 
patients as compared to the general population taking into account exposure to therapy is now 415 
 14 
required to validate our hypothesis. Future studies should explore the potential relationship 416 
between RAAS inhibition and the obesity paradox taken into account that our study was 417 
based on the cut-offs for WC and BMI that have been defined for their predictive value of 418 
health risks only but not for their capacity to predict the response to a given drug. Further 419 
analysis in larger population should be considered to challenge and potentially redefine those 420 
cut-offs in order to use WC and BMI as stratifying biomarkers when prescribing MRA 421 
therapy. 422 
 423 
Our findings should be regarded as hypothesis generating for future studies that should 424 
be designed to confirm whether HF patients with increased adiposity i.e. patients 425 
characterized by elevated MR ligand secretion, are potentially the best responders to MRA 426 
therapy. Because EMPHASIS-HF patients presenting an abdominal obesity derive greater 427 
benefit from eplerenone, future investigation should evaluate how the greater response to 428 
MRA therapy could contribute to and partly explain the so-called “obesity paradox” observed 429 
in HF populations. 50,37, 41 Our results call upon further investigations of obesity-associated 430 
measurements as potential straightforward classifiers predicting the therapeutic response to 431 
MRAs in HF patients and in other CV diseases and their respective risk factors for which MR 432 
activation has been implicated. More specifically, it is tempting to explore whether increased 433 
adiposity may also help identify responders to MRA therapy among HF patients with 434 
preserved ejection fraction, an important category of HF patients in much need for novel 435 
effective therapies. Indeed recently reported neutral results on clinical trials using MRA on 436 
HF patients with preserved ejection fraction have been yet explained by international 437 
geographic variation.51 In regard of our results, the event rates should be analysed according 438 
to difference in anthropomorphic parameters of the enrolled patients in Russia and Georgia 439 
and in American patients in the TOPCAT trial.22   440 
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Figure legends 604 
Figure 1 Cumulative Kaplan-Meier estimates of rates of the primary and secondary 605 
outcomes according to the four studied groups PLA, Placebo; EPL, Eplerenone; WC, waist 606 
circumference with NWC for normal WC group (WC < 102 cm for men and <88 cm for 607 
women) and HWC for high WC group characterized by the presence of an abdominal obesity 608 
(WC≥ 102 cm for men and ≥88 cm for women). 609 
 610 
Figure 2 Hazard ratios for studied outcomes with eplerenone versus placebo in overall 611 
population and according to specified subgroups of WC and BMI.  612 
The subgroups are based on baseline demographic and clinical characteristics. Values within 613 
the entire population are presented in gray. Values within the normal ranges of waist 614 
circumference (NWC i.e. WC<102/88 cm for men and women respectively) and body mass 615 
index (BMI<30 kg/m2) are presented in black and increased values in white (HWC i.e. WC 616 
≥102/88 cm for men and women respectively and BMI≥30kg/m2). Presented data are the 617 
results of multivariable model analysis adjusted for statistically significant covariates among 618 
those listed and tested in the statistical analysis section. Thus the total number of patients 619 
(2340) is inferior in this figure to the number of 2579 in Table 2 as the result of missing value 620 
in some patients. 621 
 622 
Figure 3: Eplerenone treatment effect according to morphometric parameters using 
restricted cubic spline  
Restricted cubic splines were drawn for the composite primary outcome to model the 
interaction between treatment and WC (A-B) or BMI (C) when both morphometric 
parameters were used as a continuous variable. Interactions are presented for male (A), 
women (B) and for both genders (C) in adjusted models. The continuous lines represent the 
hazard ratio and the dotted lines represent the confidence limits for the considered HR.  
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Figure 1 Cumulative Kaplan-Meier estimates of rates of the primary and secondary outcomes according to the four 
studied groups PLA, Placebo; EPL, Eplerenone; NWC, normal (<102/88 cm for men and women respectively) and  HWC, 
increased (≥102/88 cm for men and women respectively) waist circumference.
Figure 2 Hazard ratios for studied outcomes with eplerenone versus placebo in overall population and 
according to prespecified subgroups of WC and BMI.
The subgroups are based on baseline demographic and clinical characteristics. Values within the entire
population are presented in gray. Values within the normal ranges of waist circumference (NWC i.e.
WC<102/88 cm for men and women respectively) and body mass index (BMI<30 kg/m2) are presented in black
and increased values in white (HWC i.e. WC ≥102/88 cm for men and women respectively and BMI≥30kg/m2).
Presented data are the results of multivariable model analysis adjusted for statistically significant covariates
among those listed and tested in the statistical analysis section.
Variable
Nb of
events/pat
ients
Hazard Ratio
(95%CI)
P value 
for interaction
Overall 508/2340
WC 0.01
NWC 276/1170
HWC 232/1170
BMI 0.11
<30 404/1741
≥30 120/646
Variable
Nb of
events/patie
nts
Hazard Ratio
(95%CI)
P value 
for interaction
Overall 333/2339
WC 0.13
NWC 191/1170
HWC 142/1169
BMI 0.73
<30 263/1698
≥30 69/632
Variable
Nb of
events/pati
ents
Hazard Ratio
(95%CI)
P value
for interaction
Overall 286/2343
WC 0.09
NWC 163/1172
HWC 123/1171
BMI 0.93
<30 226/1700
≥30 59/633
Variable
Nb of
events/pati
ents
Hazard Ratio
(95%CI)
P value
for interaction
Overall 381/2421
WC 0.07
NWC 191/1212
HWC 170/1209
BMI 0.25
<30 301/1853
≥30 86/699
A  Hospitalization for HF or death from 
cardiovascular causes 
B     All cause death 
C  Death from cardiovascular causes D   Hospitalization for heart failure 
Figure 3 : Eplerenone treatment effect according to morphometric
parameters using restricted cubic spline
Restricted cubic spline were drawn for the composite primary outcome
to model the interaction between treatment and WC (A–B) or BMI (C)
when both morphometric parameters were used as continous variable.
Interactions are presented for male (A), women (B) and for both
genders (C) in adjusted models. The continuous lines represent the
hazard ratio and the dotted lines represent the confidence limits for the
considered HR.
B  Eplerenone treatment effect according to WC in women
C  Eplerenone treatment effect according to BMI in both genders
P-value for interaction 0.025
P-value for interaction 0.30
P-value for interaction 0.15
A   Eplerenone treatment effect according to WC in men
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Table 1 Baseline characteristics of the patients according to morphometric parameter subgroups.   
 
 
Characteristics NWC 
n=1284  
HWC 
n=1295 P 
BMI < 30 kg/m² 
n=1983 
BMI ≥ 30 kg/m² 
n=739 P 
 
 
Age (years)  69.1 ± 7.9 68.2 ± 7.3 0.003 69.2 ± 7.7
 
67.0 ± 7.2
 
< 0.0001  
 
Male gender (%)  85.4 70.0  < 0.0001 79.7
 
72.5
 
< 0.0001  
 
BMI (kg/m²) 25 ± 3 31 ± 4 < 0.0001 25 ± 3
 
34 ± 4
 
< 0.0001  
 
Weight (kg) 70 ± 12 89 ± 16 < 0.0001 73 ± 12
 
97 ± 14
 
< 0.0001  
 
Height (cm) 169 ± 9 170 ± 10 < 0.0001 169 ± 9
 
170 ± 10
 
0.22
 
 
 
WC (cm) 90 ± 8 109 ± 10 < 0.0001 94 ± 10
 
112 ± 11
 
< 0.0001  
 
Heart rate (beats/minutes)  71.0 ± 12.2 72.4 ± 12.4 0.01 71.5 ± 12.4
 
72.4 ± 12.6
 
0.16
 
 
 
Systolic blood pressure (mmHg)  122 ± 17 126 ± 16  < 0.0001 123 ± 17
 
127 ± 16
 
< 0.0001  
 
Systolic blood pressure ≥130  (mmHg) (%) 38.2 45.2 0.0004 38.8
 
48.7
 
< 0.0001  
 
Left ventricular ejection fraction (%)  26 ± 5 26 ± 4 0.006 26 ± 5
 
26 ± 4
 
0.03
 
 
 
Left ventricular ejection fraction<35% (%)  98.7 97.7 0.07 98.2
 
98.1
 
0.83
 
 
 
QRS duration (msec)  121 ± 46 123 ± 44 0.23 121 ± 44
 
122 ± 46
 
0.90
 
 
 
Ischemic heart disease (%) 69.9 69.3 0.74 69.9
 
66.7
 
0.10
 
 
 
Medical history (%)       
 
   
 
Hospitalization for heart failure 53.1 52.0 0.59 52.3
 
53.5
 
0.61
 
 
 
Hypertension 59.4 74.4  < 0.0001 62.7
 
76.6
 
< 0.0001  
 
Angina pectoris 43.5 45.3 0.34 42.1
 
47.2
 
0.02
 
 
 
Myocardial infarction 51.9 50.7 0.56 51.3
 
48.3
 
0.16
 
 
 
PCI 21.3 21.8 0.76 22.2
 
20.7
 
0.41
 
 
 
CABG 20.7 17.0 0.02 19.7
 
16.8
 
0.09
 
 
 
Atrial fibrillation 28.0 34.1 0.0007 28.8
 
36.4
 
0.0001  
 
Diabetes mellitus 27.0 36.2  < 0.0001 28.7
 
38.6
 
< 0.0001  
 
Stroke 8.8 10.4 0.17 9.3
 
10.9
 
0.20
 
 
 
Biology       
 
   
 
Estimated GFR (ml/min/1
.
73m
2
)  71 ± 22 71 ± 22 0.92 70 ± 22 
72 ± 22
 
0.07
 
 
 
Estimated GFR rate < 60ml/min/1
.
73m
2 
(%) 34.5 32.2 0.21 34.2 
31.0
 
0.11
 
 
 
Potassium (mmol/L)  4.3 ± 0.4  4.3 ± 0.4 0.05 4.3 ± 0.4
 
4.3 ± 0.4
 
0.52
 
 
 
Sodium (mmol/L)  139.8 ± 4.2 140.4 ± 3.8 <0.0001 139.9 ± 4.1
 
140.6 ± 3.5
 
<0.0001
 
 
 
Device therapy (%)       
 
   
 
Implantable cardioverter-defibrillation 12.9 14.4 0.27 13.4
 
13.1
 
0.86
 
 
 
Implantable cardioverter-defibrillation 
                with cardiac resynchronization 6.0 7.6 0.13 6.2 
7.4
 
0.28
 
 
 
Cardiac-resynchronization therapy 2.1 2.5 0.45 2.4
 
1.8
 
0.35
 
 
 
Medications at randomization visit (%) 
   
 
  
 
 
     Eplerenone 50.2 49.7 0.80 49.2
 
51.8
 
0.22
 
 
 
Diuretics 84.3 86.6 0.10 84.8
 
87.2
 
0.12
 
 
 
ACE inhibitor or ARB 92.1 94.4 0.02 93.3
 
93.8
 
0.65
 
 
 
Beta-blocker 87.4 87.4 1.00 86.7
 
88.7
 
0.17
 
 
 
Lipid lowering agent 63.3 62.2 0.60 63.5
 
61.5
 
0.33
 
 
NWC, normal waist circumference (WC<102cm for men and <88cm for women) and HWC, high WC (≥102cm for men and ≥88 cm for women characterizing an 
abdominal obesity); BMI, body mass index (characterizing a global obesity when BMI≥30kg/m2. ACE stands for angiotensin-converting enzyme; ARB angiotensin 
 
  Table 2: Association between eplerenone and outcomes depending on morphometric parameters  
 
Characteristics Events/patients (%) 
Crude HR 
(95%CI) P 
Multivariable 
HR (95%CI) 
  Characteristics Events/patients (%) 
Crude HR 
(95%CI) P 
Multivariable  
HR (95%CI) P  
 Primary outcome: death from cardiovascular causes or hospitalization for heart failure  
  Overall                         
  Placebo 335/1292 (25.9)         
      
  
  Eplerenone 229/1287(17.8) 0.64 (0.54 – 0.76) <0.0001 0.63 (0.52 – 0.75) <0.0001 
      
  
  NWC           BMI < 30         
  Placebo 169/640 (26.4)         Placebo 271/1008 (26.9)           
  Eplerenone 137/644 (21.3) 0.79 (0.63 – 0.99) 0.04 0.77 (0.61 - 0.98) 0.03 Eplerenone 193/975 (19.8) 0.71 (0.59 – 0.85) 0.0003 0.69 (0.57 - 0.83) 0.0001   
  HWC           BMI ≥ 30              
  Placebo 166/652 (25.5)         Placebo 85/356 (23.9)           
  Eplerenone 92/643 (14.3) 0.50 (0.39 - 0.65) <0.0001 0.48 (0.37 - 0.63) <0.0001 Eplerenone 54/383 (14.1) 0.51 (0.37 - 0.72) 0.0001 0.49 (0.35 - 0.71) 0.0001   
  Interaction EPL x WC   0.01   0.01 Interaction EPL x BMI   0.10   0.11   
  Secondary outcome: All Cause Mortality   
  Overall           
      
  
  Placebo 201/1292 (15.6)         
      
  
  Eplerenone 160/1287 (12.4) 0.77 (0.63 - 0.95) 0.01 0.76 (0.61 - 0.94) 0.01 
      
  
  NWC           BMI < 30         
  Placebo 107/640 (16.7)         Placebo 170/1008 (16.9)           
  Eplerenone 97/644 (15.1) 0.91 (0.69 - 1.19) 0.48 0.87 (0.66 - 1.16) 0.35 Eplerenone 135/975 (13.9) 0.81 (0.65 - 1.02) 0.07 0.75 (0.59 – 0.95) 0.02   
  HWC           BMI ≥ 30              
  Placebo 94/652 (14.4)         Placebo 43/356 (12.1)           
  Eplerenone 63/643 (9.8) 0.63 (0.46 - 0.87) 0.004 0.62 (0.44 - 0.87) 0.005 Eplerenone 35/383 (9.1) 0.67 (0.43 – 1.05) 0.08 0.68 (0.43 – 1.08) 0.11   
  Interaction EPL x WC   0.09   0.13 Interaction EPL x BMI   0.46   0.73   
  Cardiovascular death   
  Overall           
      
  
  Placebo 175/1292 (13.5)         
      
  
  Eplerenone 136/1287 (10.6) 0.75 (0.60 - 0.94) 0.01 0.73 (0.58 - 0.93) 0.009 
      
  
  NWC           BMI < 30         
  Placebo 91/640 (14.2)         Placebo 149/1008 (14.8)           
  Eplerenone 83/644 (12.9) 0.91 (0.68 - 1.23) 0.54 0.87 (0.64 - 1.18) 0.38 Eplerenone 116/975 (11.9) 0.80 (0.63 - 1.02) 0.07 0.73 (0.57 – 0.94) 0.02   
  HWC           BMI ≥ 30              
  Placebo 84/652 (12.9)         Placebo 36/356 (10.1)           
  Eplerenone 53/643 (8.2) 0.59 (0.42 - 0.84) 0.003 0.58 (0.40 - 0.83) 0.003 Eplerenone 30/383 (7.8) 0.69 (0.42 – 1.12) 0.13 0.71 (0.43 – 1.18) 0.19   
  Interaction EPL x WC   0.06   0.09  Interaction EPL x BMI   0.60   0.93   
  Hospitalization for HF   
  Overall           
      
  
  Placebo 238/1292 (18.4)         
      
  
  Eplerenone 151/1287 (11.7) 0.60 (0.49 – 0.73) <0.0001 0.59 (0.48 – 0.73) <0.0001 
      
  
  NWC           BMI < 30         
  Placebo 118/640 (18.4)         Placebo 194/1008 (19.3)           
  Eplerenone 89/644 (13.8) 0.74 (0.56 - 0.97) 0.03 0.71 (0.53 - 0.95) 0.02 Eplerenone 129/975 (13.2) 0.66 (0.53 - 0.83) 0.0003 0.62 (0.49 – 0.77) <0.0001   
  HWC           BMI ≥ 30              
  Placebo 120/652 (18.4)         Placebo 59/356 (16.6)           
  Eplerenone 62/643 (9.6) 0.47 (0.35 - 0.64) <0.0001 0.48 (0.35 - 0.66) <0.0001 Eplerenone 34/383 (8.9) 0.47 (0.31 - 0.71) 0.0004 0.47 (0.30 - 0.71) 0.0004   
  Interaction EPL x WC   0.03   0.07 Interaction EPL x BMI   0.15   0.25   
 
 CV, cardiovascular; HF, heart failure ; HR, hazard ratio; CI, confident interval;  BMI denotes body mass index expressed in kg/m2 NWC 
denotes normal waist circumference <102/88 cm and HWC for high waist circumference ≥102/88 cm for men and women respectively;  
 Events/patients are given  in unadjusted models  
receptor type II blocker; GFR glomerular filtration rate; PCI percutaneous coronary intervention and CABG coronary-artery bypass grafting. 
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 Table S1 Baseline characteristics of the patients according to waist circumference and to treatment per 
subgroup of waist circumference 
 
 
  NWC 
(N=1284) 
HWC 
(N=1295)  
 
Characteristics Placebo 
n=640 
Eplerenone 
n=644 p 
Placebo 
n=652 
Eplerenone 
n=643 P  
 
Age (years)  69.1 ± 7.9 69.2 ± 8.0 0.79 68.2 ± 7.2 68.1 ± 7.4 0.78 
 
 
Male gender  (%) 86.4 84.5 0.33 69.9 70.1 0.94 
 
 
BMI (kg/m²) 25 ± 3 24 ± 3 0.14 30 ± 4 31 ± 4 0.07 
 
 
Weight (kg) 70 ± 12 70 ± 12 0.35 88 ± 16 89 ± 15 0.13 
 
 
Height (cm) 169 ± 9 169 ± 9 0.86 170 ± 10 170 ± 10 0.88 
 
 
WC (cm) 90 ± 8 90 ± 8 0.38 108 ± 10 109 ± 10 0.08 
 
 
Heart rate (beats/minute)  71.2 ± 12.1 70.8 ± 12.2 0.39 72.3 ± 12.7 72.5 ± 12.1 0.47 
 
 
Systolic blood pressure (mmHg)  122 ± 17 122 ± 17 0.75 126 ± 16 127 ± 17 0.25 
 
 
Systolic blood pressure≥130  mmHg (%) 38.6 37.9 0.79 44.8 45.6 0.78 
 
 
Left ventricular ejection fraction (%)  26 ± 5 26 ± 5 0.12 26 ± 4 26 ± 5 0.87 
 
 
Left ventricular ejection fraction<35% 98.7 98.7 0.99 97.0 98.4 0.13 
 
 
QRS duration (msec)  122 ± 46 120 ± 46 0.37 123 ± 42 122 ± 45 0.34 
 
 
Ischemic heart disease (%) 68.1 71.7 0.16 68.8 69.8 0.71 
 
 
Medical history (%) 
       
 
Hospitalization for heart failure 53.0 53.3 0.92 52.8 51.3 0.60 
 
 
Hypertension 59.7 59.2 0.85 73.3 75.6 0.35 
 
 
Angina pectoris 44.7 42.2 0.38 44.0 46.7 0.34 
 
 
Mycardial infarction 50.5 53.3 0.32 51.7 49.8 0.49 
 
 
PCI 20.5 22.0 0.51 22.1 21.5 0.77 
 
 
CABG 19.3 22.2 0.20 18.4 15.6 0.17 
 
 
Atrial fibrillation 28.6 27.3 0.61 35.1 33.1 0.45 
 
 
Diabetes mellitus 25.8 28.3 0.32 32.7 39.8 0.007 
 
 
Stroke 8.2 9.4 0.45 10.8 10.0 0.64 
 
 
Biology             
 
 
Estimated GFR (ml/min/1.73m
2
)  71 ± 22 71 ± 22 0.67 70 ± 22 72 ± 22 0.12 
 
 
Estimated GFR rate <60ml/min/1.73m
2 
(%) 36.1 32.9 0.22 33.8 30.6 0.22 
 
 
Potassium (mmol/L)  4.3 ± 0.4  4.3 ± 0.4 0.56  4.3 ± 0.4  4.3 ± 0.4 0.89 
 
 
Sodium (mmol/L)  139.8 ± 4.2 139.9 ± 4.1 0.85 140.3 ± 3.6 140.5 ± 3.9 0.42 
 
 
Device therapy (%)             
 
 
Implantable cardioverter-defibrillation 13.3 12.4 0.63 14.4 14.3 0.95 
 
 
Implantable cardioverter-defibrillation 
              with cardiac resynchronization 6.3 5.7 0.68 9.3 5.9 0.02 
 
 
Cardiac-resynchronization therapy 1.1 3.0 0.02 2.2 2.9 0.49 
 
 
Medications at randomization visit (%)          
 
 
Diuretics 84.0 84.5 0.81 88.4 84.7 0.05 
 
 
ACE inhibitor or ARB 91.9 92.2 0.81 93.4 95.5 0.10 
 
 
Beta-blocker 86.5 88.3 0.35 88.1 86.7 0.46 
 
 
Lipid lowering agent 62.4 64.1 0.55 62.8 61.7 0.70 
 
 
None of the characteristics differed significantly (p<0.05) between the two treatment groups except in NWC 
group (<102cm for men and <88cm for women) for Cardiac-resynchronization therapy (p=0.018) and in HWC 
group (i.e. abdominal obesity characterized by WC≥102cm for men and ≥88 cm for women) for Implantable 
cardioverter-defibrillation with cardiac resynchronization (p=0.023) and for diabetes mellitus (p=0.007); ACE 
stands for angiotensin-converting enzyme; ARB angiotensin II–receptor type I blocker; GFR glomerular 
filtration rate; PCI percutaneous coronary intervention and CABG coronary-artery bypass grafting.  
 
   
 
 
 
 
 
 
Table S2 Selected investigator-reported adverse events and those leading to permanent withdrawal of the study 
drug, according to study groups* 
 
Adverse events 
 
NWC 
 
HWC 
 
 
 
Placebo Eplerenone 
 
Placebo Eplerenone 
 
 
Events 
(N=640) (N=642) P (N=649) (N=641) P p of interaction 
No. of patients (%) 
 
No. of patients (%) 
 
 All events 480 (75.0) 467 (72.7) 0.37 479 (73.8) 458 (71.5) 0.35 0.99 
Hyperkalaemia 23 (3.6) 59 (9.2) <0.0001 25 (3.9) 45 (7.0) 0.01 0.31 
Hypokalaemia 15 (2.3) 6 (0.9) 0.05 13 (2.0) 8 (1.3) 0.38 0.50 
Renal failure 23 (3.6) 20 (3.1) 0.65 17 (2.6) 16 (2.5) 1.00 0.83 
Hypotension 17 (2.7) 23 (3.6) 0.42 15 (2.3) 18 (2.8) 0.60 0.82 
        
 
Adverse events leading to study-drug withdrawal 
 
 
NWC 
 
HWC 
 
 
 
Placebo Eplerenone 
 
Placebo Eplerenone 
 
 
Events 
(N=640) (N=642) P (N=649) (N=641) P p of interaction 
No. of patients (%) 
 
No. of patients (%) 
 
 All events 93 (14.5) 101 (15.7) 0.59 112 (17.3) 74 (11.5) 0.004 0.01 
Hyperkalemia 5 (0.8) 9 (1.4) 0.42 7 (1.1) 6 (0.9) 1.00 0.35 
Hypokalaemia 1 (0.2) 0 (0.0) 0.50 1 (0.2) 0 (0.0) 1.00 - 
Renal failure 2 (0.3) 2 (0.3) 1.00 3 (0.5) 1 (0.2) 0.62 0.48 
Hypotension 0 (0.0) 0 (0.0) 1.00 3 (0.5) 0 (0.0) 0.25 0.98 
        
 
Adverse events 
 
 
BMI< 30 
 
BMI ≥ 30  
 
 
 
Placebo Eplerenone 
 
Placebo Eplerenone 
 
 
Events 
(N=1005) (N=971) P (N=355) (N=383) P p of interaction 
No. of patients (%) 
 
No. of patients (%) 
  
All events 754 (75.0) 704 (72.5) 0.22 249 (70.1) 274 (71.5) 0.69 0.20 
Hyperkalaemia 38 (3.8) 84 (8.7) <0.0001 12 (3.4) 25 (6.5) 0.06 0.65 
Hypokalaemia 24 (2.4) 14 (1.4) 0.14 7 (2.0) 2 (0.5) 0.10 0.34 
Renal failure 33 (3.3) 29 (3.0) 0.80 7 (2.0) 10 (2.6) 0.63 0.49 
Hypotension 30 (3.0) 39 (4.0) 0.22 7 (2.0) 6 (1.6) 0.78 0.38 
        
 
Adverse events leading to study-drug withdrawal 
 
 
BMI< 30 
 
BMI ≥ 30  
 
 
 
Placebo Eplerenone 
 
Placebo Eplerenone 
 
 
Events 
(N=1005) (N=971) P (N=355) (N=383) P p of interaction 
No. of patients (%) 
 
No. of patients (%) 
  
All events 171 (17.0) 143 (14.7) 0.18 50 (14.1) 44 (11.5) 0.32 0.81 
Hyperkalaemia 12 (1.2) 14 (1.4) 0.70 0 (0.0) 1 (0.3) 1.00 - 
Hypokalaemia 3 (0.3) 0 (0.0) 0.25 0 (0.0) 0 (0.0) 1.00 - 
Renal failure 3 (0.3) 2 (0.2) 1.00 2 (0.6) 2 (0.5) 1.00 0.83 
Hypotension 3 (0.3) 0 (0.0) 0.25 0 (0.0) 0 (0.0) 1.00 - 
BMI, body mass index expressed in kg/m2; WC, waist circumference with NWC for normal WC group i.e. < 102 cm for men and <88 cm for women and HWC for high WC group i.e. 
abdominal obesity with WC≥ 102 cm for men and ≥88 cm for women. * Patients who had received at least one dose of the study drug were included in the safety analysis. P values were 
calculated on the basis of the number of patients. When convergence problem were encountered for the p of interaction calculation, results were summarized by "-" 
Table S3 Association between eplerenone and outcomes depending on waist circumference  
 
 
 
Characteristics   Events/patients (%) Crude HR (95%CI) p Multivariable HR (95%CI) P  
 
Primary outcome: death from cardiovascular causes or hospitalization for heart failure 
1
  
 
WC Q1              
  
Placebo 74/234 (31.6)      
  
Eplerenone 59/239 (24.7) 0.80 (0.57 - 1.13) 0.20 0.70 (0.49 - 1.00) 0.05  
 
WC Q2              
  
Placebo 66/266 (24.8)      
  
Eplerenone 58/255 (22.8) 0.89 (0.63 - 1.27) 0.52 0.94 (0.64 - 1.37) 0.74  
 
WC Q3              
  
Placebo 59/256 (23.1)      
  
Eplerenone 34/249 (13.7) 0.54 (0.35 - 0.82) 0.004 0.52 (0.33 - 0.81) 0.004  
 
WC  Q4              
  
Placebo 66/261 (25.3)      
  
Eplerenone 35/223 (15.7) 0.54 (0.36 - 0.81) 0.003 0.53 (0.34 - 0.82) 0.005  
 
WC Q5              
  
Placebo 70/275 (25.5)      
  
Eplerenone 43/321 (13.4) 0.48 (0.33 - 0.71) 0.0002 0.47 (0.32 - 0.71) 0.0002  
 
Interaction EPL x WC   0.08  0.09  
 
Secondary outcomes : All cause mortality  
2          
 
WC Q1              
  
Placebo 46/234 (19.7)      
  
Eplerenone 41/239 (17.2) 0.93 (0.61 - 1.41) 0.72 0.78 (0.51 - 1.21) 0.27  
 
WC Q2              
  
Placebo 36/266 (13.5)      
  
Eplerenone 42/255 (16.5) 1.20 (0.77 - 1.87) 0.42 1.23 (0.78 - 1.95) 0.37  
 
WC Q3              
  
Placebo 46/256 (18.0)      
  
Eplerenone 26/249 (10.4) 0.54 (0.33 - 0.87) 0.01 0.50 (0.30 - 0.84) 0.008  
 
WC  Q4              
  
Placebo 34/261 (13.0)      
  
Eplerenone 18/223 (8.1) 0.56 (0.32 - 0.99) 0.05 0.54 (0.29 - 1.00) 0.05  
 
WC Q5              
  
Placebo 39/275 (14.2)      
  
Eplerenone 33/321 (10.3) 0.69 (0.44 - 1.10) 0.12 0.73 (0.45 - 1.20) 0.21  
 
Interaction EPL x WC   0.09  0.09  
 
Death from Cardiovascular causes 
3
           
 
WC Q1              
  
Placebo 40/234 (17.1)      
  
Eplerenone 37/239 (15.5) 0.96 (0.61 - 1.50) 0.86 0.82 (0.52 - 1.30) 0.39  
 
WC Q2              
  
Placebo 33/266 (12.4)      
  
Eplerenone 35/255 (13.7) 1.09 (0.68 - 1.76) 0.72 1.11 (0.68 - 1.82) 0.67  
 
WC Q3              
  
Placebo 37/256 (14.5)      
  
Eplerenone 22/249 (8.8) 0.57 (0.34 - 0.96) 0.04 0.52 (0.30 - 0.91) 0.02  
 
WC  Q4              
  
Placebo 30/261 (11.5)      
  
Eplerenone 16/223 (7.2) 0.56 (0.31 - 1.03) 0.06 0.53 (0.27 - 1.02) 0.06  
 
WC Q5              
  
Placebo 35/275 (12.7)      
  
Eplerenone 26/321 (8.1) 0.61 (0.37 - 1.01) 0.05 0.66 (0.39 - 1.12) 0.12  
 
Interaction EPL x WC   0.19  0.24  
 
 Hospitalization from heart failure 
 4          
 
WC Q1              
  
Placebo 50/234 (21.4)      
  
Eplerenone 38/239 (15.9) 0.76 (0.50 - 1.17) 0.21 0.69 (0.45 - 1.08) 0.10  
 
WC Q2              
  
Placebo 48/266 (18.1)      
  
Eplerenone 37/255 (14.5) 0.78 (0.51 - 1.20) 0.26 0.77 (0.49 - 1.21) 0.25  
 
WC Q3              
  
Placebo 41/256 (16.0)      
  
Eplerenone 22/249 (8.8) 0.50 (0.30 - 0.85) 0.01 0.56 (0.33 - 0.94) 0.03  
 
WC  Q4              
  
Placebo 48/261 (18.4)      
  
Eplerenone 26/223 (11.7) 0.55 (0.34 - 0.89) 0.01 0.56 (0.34 - 0.92) 0.02  
 
WC Q5              
  
Placebo 51/275 (18.6)      
  
Eplerenone 28/321 (8.7) 0.44 (0.27 - 0.69) 0.0004 0.42 (0.26 - 0.68) 0.0004  
 
Interaction EPL x WC  
 
0.27  0.43  
 
 Quintiles were formed by intervals defined separately by sex and than quintiles 1 to 5 were combined for men and 
women. In men quintiles were defined by Q1as WC<90cm, Q2 as 90cm≤WC<97cm, Q3 as 97cm≤WC<103cm, Q4 as 
103cm≤WC<110cm and  Q5 as WC≥110cm. In women quintiles were defined by Q1 as WC<82.53cm; Q2 as 
82.53cm≤WC<90cm; Q3 as 90cm≤WC<98cm; Q4 as 98cm≤WC<106cm and Q5 as WC≥106cm. Adjusted for: 
1
age, 
heart rate, SBP, LVEF,  eGFR, NA, hosp, Mi, Diab, Stroke, Diuretics, and BB; 
2
 age, Male, heart rate, SBP, LVEF, 
eGFR, NA, Isch-HF, hosp, Diab, Stroke, and Diuretics; 
3
 age, SBP, LVEF, NA, BB, MI, hosp, Diab, Stroke, and 
Diuretics; 
4
 age, heart rate, SBP, LVEF, eGFR,  hosp Mi, Diab, Diuretics, and BB 
 
 
 
Table S4 Association between eplerenone and outcomes depending on body mass index 
 
 
Characteristics Events/patients (%) Crude HR (95%CI) P Multivariable HR (95%CI) P 
 
 
Primary outcome: death from cardiovascular causes or hospitalization for heart failure 
 
 
Overall 
     
 
BMI < 27 339/1342 (25.3) 
     
 
BMI ≥ 27 264/1380 (19.1) 0.70 (0.60 - 0.83) <0.0001 0.74 (0.62 – 0.88) 0.0006 
 
 
Body mass index < 27 kg/m
2 
     
 
Placebo 185/666 (27.8) 
     
 
Eplerenone 154/676 (22.8) 0.79 (0.64 – 0.98) 0.03 0.76 (0.61 - 0.94) 0.01 
 
 
Body mass index ≥ 27 kg/m
2 
     
 
Placebo 171/698 (24.5) 
     
 
Eplerenone  93/682 (13.6) 0.50 (0.39 - 0.65) <0.0001 0.50 (0.38 - 0.65) <0.0001 
 
 
Interaction EPL x BMI   0.007   0.02 
 
 
Secondary outcomes :All cause mortality  
  
 
Overall 
     
 
BMI < 27 224/1342 (16.7) 
     
 
BMI ≥ 27 159/1380 (11.5) 0.65 (0.53 - 0.80) <0.0001 0.72 (0.58 – 0.89) 0.003 
 
 
Body mass index < 27 kg/m
2 
     
 
Placebo 115/666 (17.3) 
     
 
Eplerenone 109/676 (16.1) 0.92 (0.71 - 1.20) 0.56 0.82 (0.62 – 1.08) 0.16 
 
 
Body mass index ≥ 27 kg/m
2 
     
 
Placebo 98/698 (14.0) 
     
 
Eplerenone 61/682 (8.9) 0.59 (0.43 – 0.82) 0.001 0.61 (0.44 – 0.85) 0.003 
 
 
Interaction EPL x BMI   0.04   0.18 
 
 
Death from Cardiovascular causes          
 
 
Overall 
     
 
BMI < 27 197/1342 (14.7) 
     
 
BMI ≥ 27 134/1380 (9.7) 0.62 (0.50 – 0.77) <0.0001 0.68 (0.54 – 0.86) 0.001 
 
 
Body mass index < 27 kg/m
2 
     
 
Placebo 101/666 (15.2) 
     
 
Eplerenone  96/676 (14.2) 0.93 (0.70 - 1.23) 0.60 0.81 (0.60 – 1.08) 0.15 
 
 
Body mass index ≥ 27 kg/m
2 
     
 
Placebo 84/698 (12.0) 
     
 
Eplerenone 50/682 (7.3) 0.57 (0.40 – 0.81) 0.002 0.60 (0.42 – 0.87) 0.006 
 
 
Interaction EPL x BMI   0.03   0.22 
 
 
Hospitalization from heart failure         
  
 
Overall 
     
 
BMI < 27 237/1342 (17.7) 
     
 
BMI ≥ 27 179/1380 (12.9) 0.68 (0.56 – 0.83) 0.0001 0.74 (0.61 – 0.91) 0.002 
 
 
Body mass index < 27 kg/m
2 
     
 
Placebo 134/666 (20.1) 
     
 
Eplerenone 103/676 (15.2) 0.73 (0.57 - 0.95) 0.02 0.68 (0.52 – 0.88) 0.004 
 
 
Body mass index ≥ 27 kg/m
2 
     
 
Placebo 119/698 (17.1) 
     
 
Eplerenone  60/682 (8.8) 0.47 (0.34 - 0.64) <0.0001 0.44 (0.33 - 0.62) <0.0001 
 
 
Interaction EPL x BMI   0.03   0.05 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 adjusted for age, male gender, heart rate, SBP, LVEF, eGFR, medical history (Hospitalization for HF, MI, 
Diabetes mellitus, Stroke) beta blockers and diuretics; BMI denotes body mass index; CV, cardiovascular; 
HF, heart failure. 
 
 
